EA038959B1 - Способ диагностики злокачественной опухоли и набор для диагностики путем измерения активности nk-клеток - Google Patents

Способ диагностики злокачественной опухоли и набор для диагностики путем измерения активности nk-клеток Download PDF

Info

Publication number
EA038959B1
EA038959B1 EA201391187A EA201391187A EA038959B1 EA 038959 B1 EA038959 B1 EA 038959B1 EA 201391187 A EA201391187 A EA 201391187A EA 201391187 A EA201391187 A EA 201391187A EA 038959 B1 EA038959 B1 EA 038959B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
interleukin
amino acid
seq
blood sample
Prior art date
Application number
EA201391187A
Other languages
English (en)
Russian (ru)
Other versions
EA201391187A1 (ru
Inventor
Джэ Мюн Ли
Чоо Чхуун Ёон
Сан Воо Парк
Чон Сун Ким
Original Assignee
Нкмакс Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нкмакс Ко., Лтд. filed Critical Нкмакс Ко., Лтд.
Publication of EA201391187A1 publication Critical patent/EA201391187A1/ru
Publication of EA038959B1 publication Critical patent/EA038959B1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/575—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EA201391187A 2011-02-14 2012-02-10 Способ диагностики злокачественной опухоли и набор для диагностики путем измерения активности nk-клеток EA038959B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110012983A KR20120093002A (ko) 2011-02-14 2011-02-14 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
PCT/IB2012/000259 WO2012110878A2 (en) 2011-02-14 2012-02-10 Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity

Publications (2)

Publication Number Publication Date
EA201391187A1 EA201391187A1 (ru) 2013-12-30
EA038959B1 true EA038959B1 (ru) 2021-11-15

Family

ID=46672988

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391187A EA038959B1 (ru) 2011-02-14 2012-02-10 Способ диагностики злокачественной опухоли и набор для диагностики путем измерения активности nk-клеток

Country Status (20)

Country Link
US (2) US11442069B2 (enExample)
EP (1) EP2676139B1 (enExample)
JP (5) JP6629497B2 (enExample)
KR (3) KR20120093002A (enExample)
CN (1) CN103370622B (enExample)
AU (2) AU2012219184A1 (enExample)
BR (1) BR112013020454B1 (enExample)
CA (1) CA2826053C (enExample)
CL (1) CL2013002361A1 (enExample)
DK (1) DK2676139T3 (enExample)
EA (1) EA038959B1 (enExample)
ES (1) ES2797549T3 (enExample)
IL (1) IL227952B (enExample)
MX (1) MX361731B (enExample)
MY (1) MY175351A (enExample)
RU (1) RU2635194C2 (enExample)
SG (1) SG192247A1 (enExample)
TW (2) TWI668445B (enExample)
UA (1) UA120697C2 (enExample)
WO (1) WO2012110878A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
US10509034B2 (en) 2013-11-05 2019-12-17 Agency For Science, Technology And Research Bladder carcinoma biomarkers
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
WO2017204446A2 (ko) * 2016-05-24 2017-11-30 울산대학교 산학협력단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
CN106222140A (zh) * 2016-08-04 2016-12-14 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基及其配制方法
CN106085958A (zh) * 2016-08-04 2016-11-09 英普乐孚生物技术(上海)有限公司 一种nk细胞的制备方法
CN107686828A (zh) * 2016-08-04 2018-02-13 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR102090698B1 (ko) * 2017-08-24 2020-04-23 연세대학교 산학협력단 암의 진단, 모니터링, 또는 예후 예측을 위해 생체 외 인터페론-감마의 양을 측정하는 방법
NZ766453A (en) 2018-02-01 2022-02-25 Nkmax Co Ltd Method of producing natural killer cells and composition for treating cancer
JP7649244B2 (ja) * 2019-02-14 2025-03-19 リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル 免疫細胞の効力をアッセイするための刺激剤の使用
WO2021041399A1 (en) * 2019-08-29 2021-03-04 Board Of Regents, The University Of Texas System Cell cryopreservation medium
KR20220069018A (ko) * 2019-09-25 2022-05-26 레토 래버러토리즈 컴퍼니 리미티드 재조합 인터류킨-15 유사체
WO2021108389A1 (en) * 2019-11-29 2021-06-03 Nkmax Co., Ltd. Method of producing natural killer cells and compositions thereof
CN113533729B (zh) * 2021-06-15 2024-09-06 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
CN118488963A (zh) * 2021-12-17 2024-08-13 肯特大学 囊泡中生产重组生物分子的序列和方法
KR20230156518A (ko) 2022-05-06 2023-11-14 (주)다이오진 엑소좀 내의 인터페론 감마 유전자 측정을 이용한 암 조기 진단 방법 및 진단 키트
CN115247149B (zh) * 2022-08-22 2023-06-16 华域生物科技(天津)有限公司 适用于nk细胞的培养基组合物及培养方法
CN115855779A (zh) * 2023-01-18 2023-03-28 山东康华生物医疗科技股份有限公司 一种定量检测nk细胞活性的磁微粒化学发光试剂盒及其检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890009978A (ko) * 1987-12-04 1989-08-05 제임스 제이.플라인 고정화된 인터루킨(interleukin)2 및 카복실-말단에 연장 펩티드를 함유한 인터루킨2
KR100565764B1 (ko) * 2005-05-02 2006-03-28 (주)에이티젠 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및 이를포함하는 융합 단백질

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2153332C2 (ru) * 1993-08-09 2000-07-27 Орион Корпорейшн Способ сенсибилизации раковых клеток к лизису, опосредованному клетками-киллерами
DE69620877T2 (de) * 1995-02-06 2002-12-12 Genetics Institute, Inc. Arzneimittelformulierungen für il-12
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
JP3995248B2 (ja) 2001-08-13 2007-10-24 準二郎 土山 エプスタインバーウイルス陰性のｎｋ細胞株
JP2005517389A (ja) * 2001-11-20 2005-06-16 アトゲン カンパニー リミティッド 環境ストレス耐性を有する新規のペプチド及びこれを含む融合蛋白質
WO2003082206A2 (en) * 2002-03-26 2003-10-09 Centocor, Inc. Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
JP2004305095A (ja) 2003-04-07 2004-11-04 Limuloid Science Kk 細胞活性化検出方法
CN1297567C (zh) * 2003-06-13 2007-01-31 马菁 具有抗肿瘤功能的双功能融合蛋白及其制备方法和应用
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
CA2533990A1 (en) 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
MXPA06005104A (es) 2003-11-05 2007-01-25 Palingen Inc Citotoxicidad de celulas b aumentada en anticuerpos de enlace a cdim.
WO2005108423A1 (en) 2004-05-11 2005-11-17 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
JP4653465B2 (ja) 2004-10-25 2011-03-16 泰信 小林 ナチュラルキラー細胞の増殖促進方法およびそれに用いる培養組成物
EP1901766A2 (en) * 2005-04-08 2008-03-26 Morningside Venture Investments Limited Use of fril proteins for reducing the production of pro-inflammatory cytokines
EP2047246A4 (en) * 2006-07-28 2009-11-04 Univ New York State Res Found METHOD AND KITS FOR MEASURING THE LYMPHOCYTE FUNCTION
WO2008070647A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
AU2008204433B2 (en) 2007-01-11 2014-03-13 Novo Nordisk A/S Anti-KIR antibodies, formulations, and uses thereof
EP2048237A1 (en) * 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient Influenza virus for the expression of heterologous sequences
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890009978A (ko) * 1987-12-04 1989-08-05 제임스 제이.플라인 고정화된 인터루킨(interleukin)2 및 카복실-말단에 연장 펩티드를 함유한 인터루킨2
KR100565764B1 (ko) * 2005-05-02 2006-03-28 (주)에이티젠 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및 이를포함하는 융합 단백질

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
K. TAKEDA et al. Interleukin-12 is involved in the enhancement of human natural killer cell activity by Lactobacillus casei Shirota, Clinical and Experimental Immunology. 2006, Vol. 146, pp. 109-115. See the whole document, especially, pp. 109, 114 *
KIMBERLY L. KANE et al. Determination of Natural Killer Cell Function by Flow Cytometry. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY. 1996, Vol. 3, No. 3, pp. 295-300. See the whole document, especially, abstract, pp. 295, 296 *
KWANG-HO PYUN et al. Studies on the development of screening techniques for cell growth regulating factors: Development of screening systems for immune cell growth regulators and investigations for their actions. 1994. Korea Research Institute of Bioscience and Biotechnology. See the whole document *
M. FIROZ MIAN et al. Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke. Journal of Leukocyte Biology. 2008, Vol. 83, No. 3, pp. 774-784. See the whole document, especially, abstract, pp. 774, 775 *

Also Published As

Publication number Publication date
JP6629497B2 (ja) 2020-01-15
DK2676139T3 (da) 2020-06-15
TWI668445B (zh) 2019-08-11
KR20120093002A (ko) 2012-08-22
RU2013141487A (ru) 2015-03-27
TW201741670A (zh) 2017-12-01
JP2014510517A (ja) 2014-05-01
JP2017129597A (ja) 2017-07-27
JP6798922B2 (ja) 2020-12-09
CA2826053C (en) 2021-05-25
EP2676139A4 (en) 2014-12-03
SG192247A1 (en) 2013-09-30
RU2635194C2 (ru) 2017-11-09
BR112013020454A2 (pt) 2016-10-18
CN103370622B (zh) 2018-02-13
AU2017202628A1 (en) 2017-05-11
TW201245718A (en) 2012-11-16
BR112013020454A8 (pt) 2022-11-29
JP2019207242A (ja) 2019-12-05
NZ710432A (en) 2017-04-28
BR112013020454B1 (pt) 2023-03-21
CA2826053A1 (en) 2012-08-23
WO2012110878A3 (en) 2013-01-31
AU2012219184A1 (en) 2013-09-05
EP2676139A2 (en) 2013-12-25
KR101438573B1 (ko) 2014-09-12
CN103370622A (zh) 2013-10-23
UA120697C2 (uk) 2020-01-27
MY175351A (en) 2020-06-22
EA201391187A1 (ru) 2013-12-30
JP2023115006A (ja) 2023-08-18
WO2012110878A2 (en) 2012-08-23
KR20130032410A (ko) 2013-04-01
ES2797549T3 (es) 2020-12-02
US20220229070A1 (en) 2022-07-21
KR101341538B1 (ko) 2013-12-18
US12379384B2 (en) 2025-08-05
KR20130136012A (ko) 2013-12-11
MX361731B (es) 2018-12-14
JP2022043119A (ja) 2022-03-15
MX2013009380A (es) 2013-12-16
US20140017713A1 (en) 2014-01-16
EP2676139B1 (en) 2020-05-06
US11442069B2 (en) 2022-09-13
AU2017202628B2 (en) 2019-08-22
NZ614345A (en) 2015-09-25
IL227952B (en) 2019-01-31
CL2013002361A1 (es) 2014-06-27
IL227952A0 (en) 2013-09-30
TWI681191B (zh) 2020-01-01
JP7660605B2 (ja) 2025-04-11

Similar Documents

Publication Publication Date Title
JP7660605B2 (ja) がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット
JP6169101B2 (ja) 炎症性疾患の予防及び／又は治療において有用な化合物を同定するスクリーニング法
EP2880052A1 (en) Tif1-gamma for treating and diagnosing inflammatory diseases
HK1189273A (en) Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity
HK1189273B (en) Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity
NZ710432B2 (en) Method and use for measurement of nk cell activity
NZ614345B2 (en) Method and use for measurement of nk cell activity
JPWO2016035677A1 (ja) ｉｎ ｖｉｔｒｏサイクリックヌクレオチド測定の為のサンプルの前処理方法
Class et al. Patent application title: SCREENING METHODS TO IDENTIFY COMPOUNDS USEFUL IN THE PREVENTION AND/OR TREATMENT OF INFLAMMATORY CONDITIONS Inventors: Reginald Christophe Xavier Brys (Mechelen, BE) Reginald Christophe Xavier Brys (Mechelen, BE) Sonia Dupont (Romainville, FR) Assignees: GALAPAGOS NV